Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment (Q35212504)

7 August 2017

1 reference

title

Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment (English)

1 reference

7 August 2017

main subject

prostatic hypertrophy

1 reference

Claude C Schulman

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

issue

3 Suppl 1

1 reference

7 August 2017

page(s)

24-33

1 reference

Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Initial choices and final outcomes in lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Introduction and Concluding Remarks

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

1 reference

7 January 2021

Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

The pharmacovigilance of tamsulosin: event data on 12484 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Clinical comparison of selective and non‐selective &agr;1A‐adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Lower urinary tract symptoms: what are the implications for the patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

The effect of prostatectomy on symptom severity and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Sexual dysfunction in men with lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

The relationship between sexual life and urinary condition in the French community

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900471-0

7 January 2021

10.1016/S0090-4295(03)00471-0

Identifiers

DOI

1 reference

7 August 2017

1 reference